Phase 1 Study of Tazemetostat, an Enhancer of Zeste Homolog-2 Inhibitor, in Pediatric Patients With Relapsed/Refractory Integrase Inhibitor-1-Negative Tumors

Susan N. Chi1, Franck Boudreaud1, Theodore W. Laetsch2, Maryam Fouladi3, Margaret Macy4, Guy Makin5, Cynthia Wettmore6, Ashley Margolf7, Michelia Casanova8, Lindsey Killian9,10, Darren McAleer11, Geoff Cowgill12, Navin Pinto13, Dave Ebbs14,8, Giles Robinson12, Dina Wowra4,8, Margaret Macy4, Guy Makin5, Theodore W. Laetsch2, Martin Keating15,16, Margaret Macy4, Guy Makin5, Theodore W. Laetsch2, Martin Keating15,16

1.Dana-Farber Cancer Institute, Boston, MA, USA; 2.Cure Institute, Paris, France; 3.University of Texas Southwest Medical Center and Children’s Health, Dallas, TX, USA; 4.Cincinnati Children’s Hospital, Cincinnati, OH, USA; 5.Children's Hospital Colorado, Aurora, CO, USA; 6.University of Manchester, Manchester, England, UK; 7.Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 8.Philadelphia Children’s Hospital, Philadelphia, PA, USA; 9.UMCH; 10.Angeles Children’s Hospital, Los Angeles, CA, USA; 11.Fluminópolis Hospital, Florianópolis, SC, Brazil; 12.Children’s National Hospital, Washington, DC, USA; 13.“Ataxia-Telangiectasia Children’s Hospital, Houston, TX, USA; 14.Gornal-Ormond Royal Hospital for Children, London, England, UK; 15.Cancer Centre for Children at The Children’s Hospital at Westmead, Westmead, New South Wales, Australia; 16.“Seattle Children’s Hospital, Seattle, WA, USA; 17.‘Massachusetts General Hospital, Boston, MA, USA; 18.‘Jude Children’s Research Hospital, Memphis, TN, USA; 19.‘Epizyme, Cambridge, MA, USA; 20.‘Rhône-Poulenc, Copenhagen, Denmark

ABSTRACT

Tazemetostat shows promising antitumor activity in a subset of pediatric tumors, including ATRT, chondroma, and ES. The response rate observed in children with ES is comparable to that seen in adults.

KEYWORDS

ATRT, atypical teratoid rhabdoid tumor; CNS, central nervous system; CR, complete response; DOR, duration of response; ES, epithelioid sarcoma; MTD, maximum tolerated dose; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.

REFERENCES


ACKNOWLEDGMENTS

This study is sponsored by Epizyme, Inc. Third party writing assistance was provided by Ashfield Healthcare Communications, part of UDG Healthcare PLC, and funded by Epizyme, Inc.